joimax Launches iLESSYS Delta System for Treatment of Spinal Stenosis at DGNC 2015

IRVINE, Calif.–(BUSINESS WIRE)–The German company joimax®, developer of technologies and training methods for minimally invasive endoscopic spinal surgery, today announced it will introduce the company’s new iLESSYS® Delta system to the market at the 66th Annual Meeting of the German Society of Neurosurgery (DGNC) taking place in Karlsruhe, Germany from June 7-10.

iLESSYS Delta, an advanced development of the joimax iLESSYS technology, is suitable for dorsal and dorso lateral treatment of central spinal canal stenosis. The iLESSYS Delta system enables a large area to be decompressed by means of the interlaminar access, guided by endoscopic-assisted vision.

“Since the access to the spine is the same as with the already well-established iLESSYS technique, usage is very straightforward.” said Dr. Guntram Krzok, orthopedic surgeon from Waltershausen, Germany after testing the new system at a joimax workshop early this year. “I was impressed by the new scope which delivers outstanding image quality. With the specialized instrument set, it is finally possible to achieve decompression of central spinal canal stenosis.”

Advertisement

The iLESSYS Delta instrument set includes specially developed tools that enable extensive, yet gentle, tissue-sparing decompression. The 6 mm working channel of the new endoscope allows for the use of large shaver blades designed for bone resection and endo-kerrisons. An additional option is the plastic (PPSU) working tube for unimpaired X-ray examination.

“iLESSYS Delta is a logical addition to our portfolio. Not only is the system suitable for endoscopic decompression, but it also allows the parallel implantation of cages. This way we can achieve dorsal decompression and stabilization in one step,” comments Wolfgang Ries, CEO and founder of joimax.

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement